CCR2 and familial pancreatic carcinoma: Utilizing a CCR2 blocker, PF-04136309, within an orthotopic mouse model of pancreatic cancer demonstrated the ability to decelerate tumor growth and metastasis by diminishing MDSC infiltration in tumor tissues via the CCL2/CCR2 pathway (208).